^
    Back
    Association details:
    Biomarker:ATP1B1-NRG1 fusion
    Cancer:Pancreatic Cancer
    Drug:zenocutuzumab (MCLA-128) (HER2 inhibitor, HER3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

    Published date:
    04/08/2022
    Excerpt:
    Three patients with chemotherapy-resistant NRG1 fusion–positive metastatic cancer were treated with Zeno. Two patients with ATP1B1–NRG1–positive pancreatic cancer achieved rapid symptomatic, biomarker, and radiographic responses and remained on treatment for over 12 months....
    DOI:
    https://doi.org/10.1158/2159-8290.CD-21-1119
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    AACR-NCI-EORTC 2019
    Title:

    PR02 - Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

    Published date:
    10/27/2019
    Excerpt:
    A 34-year-old man with ATP1B1-NRG1 fusion-positive PDAC and longstanding tumor-associated abdominal pain also achieved rapid resolution of his pain, and normalization of CA 19-9 (418 to 11) upon treatment with MCLA-128. Imaging at 6 weeks showed tumor reduction (-22%) and that the liver metastases were non-FDG avid.